Shattuck Labs

STTK

Market cap $93.4M

Overview Fund Activity

1.95 USD

-0.19

8.88%

At close Updated Sep 17, 3:59 PM EDT

Pre-market

After hours

1.94

-0.01

0.51%

1 day

-8.88%

5 days

16.07%

1 month

91.18%

3 months

100.56%

6 months

66.67%

Year to date

61.16%

1 year

-48%

5 years

-89.92%

10 years

-89.92%

About: Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Employees: 44

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

10% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 21

5.22% less ownership

Funds ownership: 65.11% [Q1] → 59.89% (-5.22%) [Q2]

19% less funds holding

Funds holding: 75 [Q1] → 61 (-14) [Q2]

24% less capital invested

Capital invested by funds: $29.6M [Q1] → $22.7M (-$6.98M) [Q2]

56% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 25

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2

3% upside

Avg. target

$3

54% upside

High target

$4

105% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Wedbush David Nierengarten	$4	Outperform Initiated	8 Sep 2025
Leerink Partners Faisal Khurshid	$2	Outperform Maintained	14 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about STTK published over the past 30 days

Zacks Investment Research

Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?

Shattuck Labs (STTK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease —

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8–9, 2025 in Boston, MA. Conference Details Format: Panel Discussion and one-on-one meetings Session Title: TL1A: Pioneering a New MOA in IBD and Beyond Moderators: Thomas J.

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, May 01, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025 and provided recent business highlights. “All IND-enabling activities and regulatory interactions remain on-track to initiate the Phase 1 clinical trial for SL-325 in the third quarter of this year.

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325 in non-human primates (NHP). These data were featured in a digital oral presentation on February 20, 2025, during the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 in Berlin, Germany.

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

See News Rankings

Charts implemented using Lightweight Charts™